Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
Status:
RECRUITING
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
Single-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ciloleucel infusion and will be followed up to 5 years.
The total duration of the study is therefore of 7 years.
Phase:
PHASE2
Details
Lead Sponsor:
Grupo Espaol de Linfomas y Transplante Autlogo de Mdula sea
Collaborators:
Evidenze Health Espaa (CRO) Kite, A Gilead Company